Impact of a Value-Based Formulary in Three Chronic Disease Cohorts

Research presented by Kai Yeung, PharmD, PhD, scientific investigator I, Group Health Research Institute, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Related Videos

Related Content

Advertisement

November 21st 2024

FDA Approves Zanidatamab-hrii for HER2+ Biliary Tract Cancer

Cameron Santoro

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

November 19th 2024

Community Investment, Engagement Are Essential to Fully Address Cardiovascular Health Disparities

Kyle Munz

Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

November 18th 2024

KRAKEN: Oral Muvalaplin Safely Lowers Lp(a) in Early-Stage Trial

Mary Caffrey

Results bring more competition to treat this genetically driven target for cardiovascular risk.

November 18th 2024

Latest From FINEARTS-HF: No Sex-Specific Differences in Finerenone Outcomes for Heart Failure

Kyle Munz

The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.

Related Content

Advertisement

November 21st 2024

FDA Approves Zanidatamab-hrii for HER2+ Biliary Tract Cancer

Cameron Santoro

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

November 19th 2024

Community Investment, Engagement Are Essential to Fully Address Cardiovascular Health Disparities

Kyle Munz

Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

November 18th 2024

KRAKEN: Oral Muvalaplin Safely Lowers Lp(a) in Early-Stage Trial

Mary Caffrey

Results bring more competition to treat this genetically driven target for cardiovascular risk.

November 18th 2024

Latest From FINEARTS-HF: No Sex-Specific Differences in Finerenone Outcomes for Heart Failure

Kyle Munz

The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.